Adeona completes enrollment partly 2 CopperProof-2 clinical study Adeona Pharmaceuticals.

A little and uncontrolled zinc therapy research in Alzheimer’s disease patients published in 1992 demonstrated cognitive improvements in 80 percent of subjects. In some topics, the improvement was detectable after just 3 months of administering injectable zinc. Alzheimer’s disease can affect the entire brain nonetheless it is particularly associated with loss of cells in the hippocampus, the area in the brain in charge of several functions including short-term memory retention and processing. The hippocampus has among the highest concentrations of zinc in the brain. Hippocampal zinc is considered to play a role in hundreds of protecting enzymes and various other systems, including those that detoxify amyloid beta, an abnormally folded peptide that accumulates in aging and is a biomarker for Alzheimer’s disease.When it found market first, Merck set the Average Wholesale Cost of Isentress at $12,150 per patient yearly. Public applications are the largest purchaser of ARV medications in the united states, with Medicare and Medicaid the single largest payer for HIV/AIDS care in the U.S. The Department of Individual and Health Providers treatment guidelines include several preferred treatment options for first-line patients. These options provide the same clinical advantage as Isentress but cost a lower amount. Today Merck released its 4th quarter 2009 earnings earlier, 16 February, 2010. Isentress has now exceeded $1 billion in total sales (U.S. Isentress was accepted for market in October 2007, so this is approximately $1 billion in sales in 2 years.

AVEO to present data on tivozanib Stage 1b trial for breast cancer at SABCS Symposium AVEO Pharmaceuticals, Inc.